282 related articles for article (PubMed ID: 25043939)
1. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.
Mc Guire C; Elton L; Wieghofer P; Staal J; Voet S; Demeyer A; Nagel D; Krappmann D; Prinz M; Beyaert R; van Loo G
J Neuroinflammation; 2014 Jul; 11():124. PubMed ID: 25043939
[TBL] [Abstract][Full Text] [Related]
2. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
4. Mepazine Inhibits RANK-Induced Osteoclastogenesis Independent of Its MALT1 Inhibitory Function.
Meloni L; Verstrepen L; Kreike M; Staal J; Driege Y; Afonina IS; Beyaert R
Molecules; 2018 Nov; 23(12):. PubMed ID: 30513612
[TBL] [Abstract][Full Text] [Related]
5. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.
Jaworski M; Marsland BJ; Gehrig J; Held W; Favre S; Luther SA; Perroud M; Golshayan D; Gaide O; Thome M
EMBO J; 2014 Dec; 33(23):2765-81. PubMed ID: 25319413
[TBL] [Abstract][Full Text] [Related]
6. MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-κB signaling.
Elton L; Carpentier I; Staal J; Driege Y; Haegman M; Beyaert R
FEBS J; 2016 Feb; 283(3):403-12. PubMed ID: 26573773
[TBL] [Abstract][Full Text] [Related]
7. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination.
Mc Guire C; Wieghofer P; Elton L; Muylaert D; Prinz M; Beyaert R; van Loo G
J Immunol; 2013 Mar; 190(6):2896-903. PubMed ID: 23401595
[TBL] [Abstract][Full Text] [Related]
8. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
11. MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.
Demeyer A; Skordos I; Driege Y; Kreike M; Hochepied T; Baens M; Staal J; Beyaert R
Front Immunol; 2019; 10():1898. PubMed ID: 31474984
[TBL] [Abstract][Full Text] [Related]
12. Normal lymphocyte homeostasis and function in MALT1 protease-resistant HOIL-1 knock-in mice.
Skordos I; Driege Y; Haegman M; Kreike M; Staal J; Demeyer A; Beyaert R
FEBS J; 2023 Apr; 290(8):2032-2048. PubMed ID: 36479846
[TBL] [Abstract][Full Text] [Related]
13. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation.
Gewies A; Gorka O; Bergmann H; Pechloff K; Petermann F; Jeltsch KM; Rudelius M; Kriegsmann M; Weichert W; Horsch M; Beckers J; Wurst W; Heikenwalder M; Korn T; Heissmeyer V; Ruland J
Cell Rep; 2014 Nov; 9(4):1292-305. PubMed ID: 25456129
[TBL] [Abstract][Full Text] [Related]
14. MALT1 protease: a new therapeutic target in B lymphoma and beyond?
McAllister-Lucas LM; Baens M; Lucas PC
Clin Cancer Res; 2011 Nov; 17(21):6623-31. PubMed ID: 21868762
[TBL] [Abstract][Full Text] [Related]
15. The Paracaspase MALT1.
Hachmann J; Salvesen GS
Biochimie; 2016 Mar; 122():324-38. PubMed ID: 26386283
[TBL] [Abstract][Full Text] [Related]
16. The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Brüstle A; Brenner D; Knobbe CB; Lang PA; Virtanen C; Hershenfield BM; Reardon C; Lacher SM; Ruland J; Ohashi PS; Mak TW
J Clin Invest; 2012 Dec; 122(12):4698-709. PubMed ID: 23114599
[TBL] [Abstract][Full Text] [Related]
17. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis.
Dumont C; Sivars U; Andreasson T; Odqvist L; Mattsson J; DeMicco A; Pardali K; Johansson G; Yrlid L; Cox RJ; Seeliger F; Larsson M; Gehrmann U; Davis AM; Vaarala O
PLoS One; 2020; 15(9):e0222548. PubMed ID: 32870913
[TBL] [Abstract][Full Text] [Related]
18. The paracaspase MALT1: biological function and potential for therapeutic inhibition.
Jaworski M; Thome M
Cell Mol Life Sci; 2016 Feb; 73(3):459-73. PubMed ID: 26507244
[TBL] [Abstract][Full Text] [Related]
19. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts.
Govender L; Mikulic J; Wyss JC; Gaide O; Thome M; Golshayan D
Front Immunol; 2020; 11():576651. PubMed ID: 33042160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
